These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2099963)

  • 1. Effects of defibrotide after oral and parenteral administration in patients with peripheral obliterative arterial disease (POAD).
    Craveri A; Tornaghi G; Ranieri R; Stanzani M; Landi G; Paganardi L; Passaretti B; Gallo E
    Int Angiol; 1990; 9(4):274-7. PubMed ID: 2099963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of defibrotide on physical performance and hemorheologic picture in patients with peripheral arteriopathy.
    Marrapodi E; Leanza D; Giordano S; Nazzari M; Corsi C
    Clin Trials Metaanal; 1994 Apr; 29(1):21-30. PubMed ID: 10150182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
    Strano A; Fareed J; Sabbá C; Albano O; Allegra C; Carlizza A; Binaghi F; Fronteddu F; Del Guercio R; Arpaia MR
    Semin Thromb Hemost; 1991; 17 Suppl 2():228-34. PubMed ID: 1948094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral and intravenous defibrotide on blood viscosity in patients with peripheral obliterative arterial disease.
    Belfiglio A; Traietti P; Bologna E; Salvo G
    Clin Ther; 1989; 11(4):479-84. PubMed ID: 2776165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot evaluation of the effect of defibrotide in patients affected by peripheral arterial occlusive disease.
    Sabbá C; Zupo V; Dina F; Nazzari M; Albano O
    Int J Clin Pharmacol Ther Toxicol; 1988 May; 26(5):249-52. PubMed ID: 3045026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experience in patients with chronic peripheral obliterating arteriopathy: defibrotide versus definite molecular weight heparan sulfate (MW 7500-15000 dalton)].
    Michelini S; Micci A; Failla A; Grechi G; Iantaffi A
    Minerva Cardioangiol; 1996; 44(1-2):33-7. PubMed ID: 8767620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defibrotide and peripheral obliterative arterial disease: preliminary data.
    Arosio E; Pancera P; Zannoni M; Arcaro G; Priante F; Lechi A
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):526-9. PubMed ID: 2533180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease.
    Strano A; Hoppensteadt D; Walenga JM; Fareed J; Sabbá C; Berardi E; Allegra C; Carlizza A; Binaghi F; Fronteddu F; Del Guercio R; Del Guercio M; Pinto A; Alletto G; Nazzari M; Ferrari PA
    Semin Thromb Hemost; 1996; 22 Suppl 1():35-40. PubMed ID: 8807727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C
    Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tissue plasminogen activator inhibitor by defibrotide in atherosclerotic patients.
    Violi F; Ferro D; Alessandri C; Quintarelli C; Saliola M; Balsano F
    Semin Thromb Hemost; 1989 Apr; 15(2):226-9. PubMed ID: 2501872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs.
    Avellone G; Mandalà V; Pinto A; Martino A; Strano A
    Haemostasis; 1986; 16 Suppl 1():55-8. PubMed ID: 2423422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
    Echart CL; Graziadio B; Somaini S; Ferro LI; Richardson PG; Fareed J; Iacobelli M
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
    Allegra C; Antignani PL; Schachter I; Koverech A; Messano M; Virmani A
    Ann Vasc Surg; 2008; 22(4):552-8. PubMed ID: 18502605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of a transient intravenous infusion of isozsuprin on the peripheral blood flow in patients suffering from arterial occlusive disease of the limbs. A contribution to the effect of systemically-administered vasoactive drugs].
    Ehringer H; Scheiber V
    Wien Klin Wochenschr; 1972 Dec; 24(50):801-8. PubMed ID: 4642105
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombin and platelet inhibition with low-dose calcium-heparin in comparison with ASA in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class.
    Allegra C; Pollari G; Carioti B; Sardina M
    Int J Clin Pharmacol Ther; 1994 Dec; 32(12):646-51. PubMed ID: 7881702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micro- and macrocirculatory, and biohumoral changes after a month of physical exercise in patients with intermittent claudication.
    Pancera P; Prior M; Zannoni M; Lucchese L; De Marchi S; Arosio E
    Scand J Rehabil Med; 1995 Jun; 27(2):73-6. PubMed ID: 7569823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of the administration of buflomedil-hydrochloride on the arterial circulation of the legs in patients with obliterative arteriopathies].
    Tallarida G; Baldoni F; Peruzzi G; Raimondi G; Grimaldi I; Visigalli G; Gristina S; Massaro M; De Martinis L; Sangiorgi M
    Cardiologia; 1983 Aug; 28(8):651-60. PubMed ID: 6687209
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.
    Violi F; Ferro D; Saliola M; Quintarelli C; Basili S; Balsano F
    Eur J Clin Pharmacol; 1992; 42(4):379-83. PubMed ID: 1516602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of chronic obliterative arteriopathy of the legs in the second Fontaine's stage. Personal experience with a buflomedil-pentoxifylline-defibrotide combination].
    Marci M; Albiani B; Ricci M; Russo F
    Clin Ter; 1995 Mar; 146(3):211-4. PubMed ID: 7789083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.